Objective: To investigate the mechanism of shed syndecan-4 (sSDC4) in temporomandibular joint osteoarthritis (TMJOA) in rats, aiming to provide experimental evidence for its prevention and treatment. Methods: This study was approved by the Institutional Animal Ethics Committee. Twelve 6-week-old female Sprague Dawley (SD) rats were randomly divided into two groups. They received a single intra-articular injection into the bilateral superior cavity of temporomandibular joint, which consisted of either 50 μL of 4 mg/mL monosodium iodoacetate (TMJOA model group) or 50 μL of phosphate-buffered saline (PBS, control group). After 4 weeks, the mandibular condylar cartilage was harvested for hematoxylin & eosin (H&E) staining, Safranin O-fast green (SO) staining, and type II collagen (Col-Ⅱ) immunohistochemical staining to assess the degree of cartilage degeneration. The synovium of the temporomandibular joint was collected for immunohistochemical staining to detect the expression levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) to evaluate the degree of synovial inflammation. Synovial fluid from the temporomandibular joint cavity was collected to measure sSDC4 levels by enzyme-linked immunosorbent assay (ELISA). In addition, 12 6-week-old female SD rats were randomly divided into a His-SDC4 group and a control group, receiving injections into the bilateral superior cavity of temporomandibular joint of either 100 ng/mL (50 μL) of His-SDC4 protein or 50 μL of PBS once every 3 days for a total of 28 days. The same experimental procedures were performed for H&E staining, SO staining, and immunohistochemical staining (Col-Ⅱ IL-6, TNF-α) to observe condylar cartilage degeneration and detect synovial inflammation. Rat synovial fibroblasts and condylar chondrocytes were cultured in vitro and randomly divided into a His-SDC4-stimulated (10 ng/mL) group and control group. Perform CCK-8 cytotoxicity assays and observe cellular morphology under optical microscopy, the mRNA expression levels of IL-6 and TNF-α were detected by real-time quantitative polymerase chain reaction (RT-qPCR), and the levels of IL-6 and TNF-α in cell culture supernatants were measured by ELISA. Results: Compared with the control group, the TMJOA group showed decreased condylar cartilage thickness, percentage of SO-positive area, and percentage of Col-Ⅱ-positive area (all P<0.001); an increased synovitis score (P<0.001) and increased percentages of IL-6- and TNF-α-positive cells in the synovium (all P<0.001); and a significant increase in sSDC4 levels in the synovial fluid (P=0.011). Following intra-articular injection of His-SDC4, condylar cartilage thickness, percentage of SO-positive area, and percentage of Col-Ⅱ-positive area all decreased (all P<0.001); the synovitis score increased (P=0.006), and the percentages of IL-6- and TNF-α-positive cells in the synovium increased (all P<0.001). In vitro experiments showed that His-SDC4 stimulation significantly upregulated the expression levels of IL-6 and TNF-α in both synovial fibroblasts and condylar chondrocytes (all P<0.01), and the levels of these two cytokines in the culture supernatants also significantly increased (all P<0.01). Conclusion During TMJOA progression, the level of sSDC4 in the synovial fluid is significantly elevated, which can directly stimulate synovial fibroblasts and condylar chondrocytes to secrete more pro-inflammatory cytokines, forming a vicious cycle that accelerates TMJOA progression.

Varicella, often referred to as chickenpox, is a widespread acute infectious condition triggered by the varicella-zoster virus (VZV). It manifests with systemic symptoms and distinct skin and mucosal eruptions, including macules, papules, and vesicles. Although it mainly affects children, the disease is typically more severe in teenagers and adults. Following the adoption of vaccine-based control measures in China, there has been a noticeable trend of varicella affecting older demographics, leading to an uptick in cases among teenagers and adults. This review synthesizes the latest research on the clinical symptoms, epidemiological trends, and immunization strategies for varicella in these age groups, both domestic and aboard. The goal is to enhance strategies for prevention and control, support the development of tailored immunization policies, and underscore the critical role of the varicella vaccine in comprehensive health management across all ages.

This study started from the connotation of public welfare and, from the perspective of equal rights and responsibilities, interpreted the public welfare responsibilities and entitlements of hospitals. It developed corresponding quantitative measurement tools and constructed a Public Welfare Rights and Responsibilities Index. Public welfare responsibilities were reflected in the provision of equitable, accessible, appropriate, and reasonable basic medical and public health services. These responsibilities were quantified using the market price of basic medical services, the average cost per case-mix index unit, and public service expenditures. Entitlements were reflected in financial subsidies, tax exemptions, and land policy support. Based on this framework, the study applies the Public Welfare Rights and Responsibilities Index to evaluate 147 public hospitals in City S from 2019 to 2021. The results show that the overall level of public welfare among public hospitals in City S was relatively high (with an average index of 2.39), but showed a slight downward trend. Differences were observed across hospital grades and types, with secondary-level hospitals and general hospitals demonstrating relatively higher levels of public welfare. This study could provide a practical and quantifiable method for measuring hospital public welfare within an equal rights and responsibilities framework, offering a novel analytical tool and empirical evidence to support policy formulation and performance evaluation.

Objective:To analyze the coordination between the growth of per capita health expenditure and per capita gross domestic product (GDP) in China from 2012 to 2021, and to explore the changes and regional disparities in the health consumption elasticity coefficient.Methods:Descriptive analysis was used to compare the average annual growth rates of per capita health expenditure and per capita GDP between 2012-2019, Pearson correlation analysis was conducted to test the relationship between the two variables. The health consumption elasticity coefficient was calculated as the ratio of the growth rates of health expenditure to GDP, and its temporal changes and regional distribution characteristics were analyzed.Results:After adjusting for price factors, the average annual growth rate of per capita health expenditure in China from 2012 to 2021 was 9.11%, higher than that of per capita GDP (6.11%), with no correlation between the two variables ( r=0.30, P>0.05). The national average health consumption elasticity coefficient was 1.49, lower than that in 2012-2019 (1.60), indicating an improvement in coordination. Compared with developed countries, China′s elasticity coefficient was at a moderate level. Conclusions:Overall, the growth of health expenditure in China remains faster than that of economic growth, with certain regional differences, but the degree of coordination has improved compared with the previous period.

Objective:To construct and validate an age-specific medical expenditure index for analyzing healthcare cost differences across age groups.Methods:Data on demographics and costs from 1.8162 million residents covered by urban and rural residents′ basic medical insurance in a city of Zhejiang Province in 2019, 2021, and 2022 were analyzed. Average per capita medical costs were calculated for each single-year age group. The arithmetic mean of per capita medical expenditure for each age group was determined, and the medical cost of the age group closest to this average was used as the reference value to calculate the relative medical expenditure index for each group. Validation was conducted using data from a district in Guangdong province for 2022-2023.Results:The average per capita cost for the entire sample in the city of Zhejiang province was 3 692.20 yuan, with the 54-year-old age group having the closest cost to this value, thus serving as the reference for calculating age-specific medical expenditure index. The 14-year-old age group had the lowest medical expenditure index at 0.190, while the 84-year-old group had the highest at 2.638. The life-cycle medical expenditure index totaled 89.942, corresponding to 317 528.80 yuan. Cumulative indices by life stage were 7.724 (children, 0-19 years old), 9.455 (young adults, 20-39 years old), 17.993 (middle-aged, 40-59 years old), 39.543 (younger elderly, 60-79 years old), and 15.227 (older elderly, ≥80 years old), accounting for 8.59%, 10.51%, 20.01%, 43.96%, and 16.93% of the full life-cycle cost. Validation showed similar index patterns between the two regions before the age of 60, with slight differences in the elderly stage.Conclusions:The age-specific medical expenditure index could reflect the impact of age structure on healthcare costs and provide a practical tool for estimating medical insurance funding and optimizing healthcare resource allocation.

Objective:To develop a financing model for the urban and rural residents′ basic medical insurance (URBMI) based on medical service costs, providing a scientific foundation for achieving a balance between fund revenue and expenditure.Methods:Drawing on operational experience from regional hospitals, 10 key factors influencing URBMI fund expenditures were distilled: the number of hospital beds per thousand population, annual hospitalization rates per hundred population, average length of stay, bed occupancy rate, county-level hospitalization rate, regional age-specific medical expenditure index, proportion of hospital personnel costs in medical revenue, number of hospital staff per bed, average annual personnel costs per employee, and the average reimbursement rate for insured individuals. Based on these 10 key factors, a URBMI financing model for a sample region was developed, and the reasonable per-capita medical expenditure and the sustainability threshold of per-capita financing were preliminarily estimated.Results:Model calculations revealed that the predicted reasonable per-capita medical expenditure of the sample county was 4 140.9 yuan. Assuming an average reimbursement rate of 50% for URBMI enrollees, the per-capita financing requirement was at least 2 070.5 yuan. Sensitivity analysis showed that the sustainability threshold of per-capita financing was more sensitive to changes in average length of stay and the proportion of hospital personnel costs in medical revenue.Conclusions:This study constructed a URBMI financing model based on 10 key factors affecting fund expenditures. By adjusting regional characteristic variables, the model can reflect how regional economic conditions and health-care needs influence URBMI financing requirements.

Objective:To explore differences in dose-adjusted plasma concentrations of valproic acid between different valproate formulations in patients with mental disorders based on therapeutic drug monitoring data.Methods:A retrospective analysis was performed; clinical data, including demographic characteristics, therapeutic drug monitoring results, comorbidities, medication details (daily valproic acid dose, concomitant medications), and liver and kidney function indicators, were collected from 633 patients with bipolar disorder or schizophrenia who were hospitalized at Xi'an Mental Health Center and received different valproates from January 2024 to June 2024 (98 patients receiving sodium valproate and 535 receiving magnesium valproate). Clinical data between a sodium valproate group and a magnesium valproate group were compared. Multivariate linear regression was used to identify independent influencing factors for dose-adjusted plasma concentration of valproic acid. Valproic acid daily doses, and plasma concentrations and dose-adjusted plasma concentrations of valproic acid were compared between the two groups, with subgroup analyses conducted by gender and age categories.Results:A total of 658 measurements of plasma valproic acid concentration were obtained in 633 patients, including 104 measurements in the sodium valproate group and 554 in the magnesium valproate group. Significant differences in proportions of comorbidities and concomitant use of olanzapine, quetiapine and clozapine were observed between the sodium valproate group and magnesium valproate group ( P<0.05). After adjusting for age, gender, body mass index, comorbidities, concomitant medications, and liver and kidney function indicators, the type of valproates remained an independent influencing factor for dose-adjusted plasma concentration of valproic acid (adjusted unstandardized B coefficient=13.814, 95% CI: 8.090-19.540, P<0.001). Daily dose in the sodium valproate group (1.0[1.0, 1.0] g/d) was significantly higher than that in the magnesium valproate group (0.5[0.5, 1.0] g/d), and dose-adjusted plasma concentration of valproic acid in the magnesium valproate group (93.00 [75.60, 117.40] [μg/mL]/[g·d]) was statistically higher than that in the sodium valproate group (78.55 [57.90, 90.00][μg/mL]/[g·d], P<0.05). Subgroup analysis revealed that, among patients stratified by genders and ages (<40 years vs. ≥40 years), the daily dose in the sodium valproate group was significantly higher than that in the magnesium valproate group, while the dose-adjusted plasma concentration of valproic acid in the magnesium valproate group was significantly higher than that in the sodium valproate group ( P<0.05). Conclusion:Significant differences in dose-adjusted plasma concentrations of valproic acid are observed among different valproate formulations for the treatment of mental disorders; therefore, therapeutic drug monitoring should be performed in patients when switching valproates to facilitate precise individualized dosage adjustment.

Objective The causal relationship between immune cells and hepatocellular carcinoma(HCC)risk was investigated using a two-sample Mendelian randomization method.Methods The datasets including 731 immune cells and HCC were obtained from the GWAS database and Finngen database,respectively.The stability and reliability of Mendelian randomization studies were evaluated by the MR-Egger regression,MR PRESSO,Cochran's Q test,and leave one out test.The inverse variance weighting,MR-Egger,weigh-ted median,simple mode and weighted mode were used to investigate the causal relationship between immune cells and HCC.Results A total of 4 immune cells were found to have a potential causal relationship with HCC,and the results were stable.The CD3+CD39+Treg,CD80+granulocyte and CD4+Treg were protective factors for HCC(OR=0.910,95%CI:0.852-0.972;OR=0.919,95%CI:0.865-0.975;OR=0.924,95%CI:0.873-0.978),while CD45+CD33+HLA-DR+CD14+marrow cells were a risk factor for HCC(OR=1.116,95%CI:1.033-1.204).Conclusion The CD3+CD39+Treg,CD80+granulocytes,and CD4+Treg are negatively associated with the risk of HCC,while CD45+CD33+HLA-DR+CD14+marrow cells are positively associated with the risk of HCC.

Objective:To evaluate the safety and efficacy of accelerator-based boron neutron capture therapy (AB-BNCT) in the treatment of recurrent and refractory malignant tumors.Methods:The data of 14 patients admitted to Xiamen Humanity Hospital from September 2022 to April 2023 were prospectively collected, including 7 patients with primary brain malignancies and 7 patients with locally recurrent inoperable head and neck malignancies. All patients received intravenous infusion of boron drug (NBB-001, p-dihydroxyborylphe nylalanine, a patented freeze-dried formulation) at a total nominal dosage of 500 mg/kg (11 patients) or 750 mg/kg (3 patients), and were irradiated with neutrons (operating with NeuPex system). Adverse events after treatment were recorded and assessed. The primary efficacy endpoint was the 90 d objective response rate (ORR), while the secondary endpoints included progression-free survival (PFS) and complete response rate (CRR). Data were compiled and analyzed by SAS 9.4 software. The rate and 95% CI were calculated using Clopper-Pearson method. Results:The median dose delivered to 80% of the target volume (D 80%) was 16.80 GyE (range: 8.93-23.79 GyE). The most common adverse reactions were hyperamylasemia, alopecia, and hyperprolactinemia. Five patients experienced 8 cases of grade 3 or above adverse events, including 1 case of grade 4 acute kidney injury and 7 cases of grade 3 adverse events. All adverse events were recovered after observation or treatment. At 90 d after treatment, the ORR of all patients was 9/14 (64%, 95% CI: 35%-87%), disease control rate (DCR) was 10/14 (71%, 95% CI: 42%-92%), CRR was 2/14 (14%, 95% CI: 2%-42%); and the best overall response during the entire course included an ORR of 10/14 (71% ,95% CI: 42%-92%), DCR of 13/14 (93%, 95% CI: 66%-100%), and CRR of 3/14 (21% ,95% CI: 5%-51%). The 1-year survival rate for head and neck malignancies was 71.4%, and the 2-year survival rate was 42.8%. The 1-year survival rate for recurrent brain malignancies was 42.8%. Conclusion:AB-BNCT demonstrates favorable safety and promising efficacy in treating primary brain malignancies and recurrent/refractory head and neck malignancies, representing a potential therapeutic option.

Objective The causal relationship between immune cells and hepatocellular carcinoma(HCC)risk was investigated using a two-sample Mendelian randomization method.Methods The datasets including 731 immune cells and HCC were obtained from the GWAS database and Finngen database,respectively.The stability and reliability of Mendelian randomization studies were evaluated by the MR-Egger regression,MR PRESSO,Cochran's Q test,and leave one out test.The inverse variance weighting,MR-Egger,weigh-ted median,simple mode and weighted mode were used to investigate the causal relationship between immune cells and HCC.Results A total of 4 immune cells were found to have a potential causal relationship with HCC,and the results were stable.The CD3+CD39+Treg,CD80+granulocyte and CD4+Treg were protective factors for HCC(OR=0.910,95%CI:0.852-0.972;OR=0.919,95%CI:0.865-0.975;OR=0.924,95%CI:0.873-0.978),while CD45+CD33+HLA-DR+CD14+marrow cells were a risk factor for HCC(OR=1.116,95%CI:1.033-1.204).Conclusion The CD3+CD39+Treg,CD80+granulocytes,and CD4+Treg are negatively associated with the risk of HCC,while CD45+CD33+HLA-DR+CD14+marrow cells are positively associated with the risk of HCC.